What type of merger is Sun Pharma and Ranbaxy?
Mia Smith
Published Feb 25, 2026
What type of merger is Sun Pharma and Ranbaxy?
Post Merger Integration
Sun Pharma Ranbaxy : Post Merger Integration.
When did Sun Pharma acquire Ranbaxy?
Sun Pharma completed the acquisition of Ranbaxy Laboratories Limited, an integrated, research based, international pharmaceutical company, on 25th March 2015.
Why did Sunpharma acquire Ranbaxy?
To increase presence in global and domestic markets, Sun Pharmaceutical Industries is buying Ranbaxy Laboratories in a shareswap deal. This is because its total equity value is $3.2 billion and the deal size is $4 billion (valuing Ranbaxy at 2.2 times last 12 months sales).
What is the salary of CEO of Sun Pharma?
Dilip Shanghvi, promoter and Managing Director of Sun Pharmaceutical Industries (Sun Pharma), forewent 99 percent of his FY19 salary as India’s largest drug maker optimised operational costs due to pricing pressure and moderating growth in US. Shanghvi took home Re 1 as salary in FY19 from around Rs 3 crore in FY18.
Who is the owner of Ranbaxy?
Sun Pharmaceutical Industries Ltd.
Daiichi Sankyo
Ranbaxy Laboratories/Parent organizations
In 2008, Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in Ranbaxy and in 2014, Sun Pharma acquired 100% of Ranbaxy in an all-stock deal.
What is horizontal mergers?
A Horizontal merger is a merger between firms that produce and sell the same products, i.e., between competing firms. Horizontal mergers, if significant in size, can reduce competition in a market and are often reviewed by competition authorities.
What is the product of Ranbaxy?
Showing 1 to 25 of 423 entries
| Name | Form | MRP |
|---|---|---|
| DOBESIL OINTMENT 0.5% Comp: Calcium dobesilate 0.5 %W/W Form: OINTMENT MRP: 39.00 | OINTMENT | 39.00 |
| DOLIZA ER 650MG TAB Comp: Acetaminophen 650 MG Form: TABLET MRP: 20.00 | TABLET | 20.00 |
| DOLIZA PLUS TAB Comp: Aceclofenac 100 MG+Paracetamol 500 MG Form: TABLET MRP: 16.00 | TABLET | 16.00 |
Who is the CEO of Sun Pharma?
Dilip Shanghvi
Sun Pharma
| Type | Public |
|---|---|
| Area served | Worldwide |
| Key people | Dilip Shanghvi (CEO) |
| Products | Pharmaceuticals generic drugs over-the-counter drugs vaccines diagnostics contact lenses animal health |
| Revenue | ₹334.73 billion (US$4.4 billion) (2020) |
Who is owner of Sun Pharma?
Dilip Shanghvi is the founder of Sun Pharmaceutical Industries Ltd. and has extensive industrial experience in the pharmaceutical industry.
Is Shivinder Mohan Singh still in jail?
He is currently under arrest for criminal breach of trust along with his brother Malvinder Mohan Singh….
| Shivinder Mohan Singh | |
|---|---|
| Children | 4 |
What are the 4 types of mergers?
Types of Mergers
- Horizontal – a merger between companies with similiar products.
- Vertical – a merger that consolidates the supply line of a product.
- Concentric – a merger between companies who have similar audiences with different products.
- Conglomerate – a merger between companies who offer diverse products/services.
When did Sunsun Pharma acquire Ranbaxy?
Sun Pharma completed the acquisition of Ranbaxy Laboratories Limited, an integrated, research based, international pharmaceutical company, on 25th March 2015. Information and announcements about this can be found on this page.
What are Sun Pharma’s acquisitions?
In the past three decades, Sun Pharma ha s through joint ventures and acquisitions in India and abroad 12. It acquired Dadha Pharma to commence operations into oncology and gynecology. Other acquisitions include Gujarat Lyka Organic Ltd, and MJ Pharma in India and Taro Pharmaceutical and Caraco in the US.
What is the difference between Sunsun and Ranbaxy?
Sun’s domestic portfolio has a bias towards specialties including cardiovascular and oral anti-diabetes while Ranbaxy’s domestic portfolio has large primary care and over-the-counter segments as well. Sun will benefit from Ranbaxy’s distribution network as well. Ranbaxy has a strong reach in the rural markets.
Who is the parent company of Ranbaxy?
Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures, and alliances, ground operations in 43 countries and 21 manufacturing facilities spread across 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group.
